Vivaldi Biosciences

Vivaldi Biosciences is developing vaccines for protection against epidemic and pandemic viral respiratory diseases using its Delta NS1 vector and innovative cell-based production technologies. Vivaldis DeltaFLU universal influenza vaccine is in Phase 2 clinical development. Its Delta-19 universal influenza/Covid-19 vaccine will enter clinical trials in 2021. Delta NS1 is a versatile and robust technology platform for self-adjuvanting vaccines administered by nasal spray. Delta NS1 is a replication-deficient vaccine vector based on a genetically modified, safely attenuated influenza virus strain. Delta NS1-based vaccines have the unique ability to rapidly induce interferon, generating protection against circulating viruses entering the nasal passages, and...

Virology,cell-based manufacture,covid-19 vaccine,influenza vaccine,and universal influenza vaccine

Vivaldi biosciences operates in the Biotechnology research industry.

Vivaldi biosciences's revenue is 11m - 100m

Vivaldi biosciences has 11 - 50 employees.